Ironwood Pharma (IRWD) Misses Q2 EPS by 4c, Revenues Miss; Offers 2018 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update
August 6, 2018 8:00 AM EDTSecond quarter revenue increased 25% year-over-year to $81 million, driven primarily by LINZESS® (linaclotide) U.S. net sales of $192 million and commercial margin of 60%
Terminating licensing agreement with AstraZeneca for U.S. lesinurad franchise
Initiated Phase III programs with IW-3718 and linaclotide and advanced four Phase II trials with lead sGC stimulators, praliciguat and olinciguat
On track to complete separation of Ironwood into two independent, publicly traded companies in first half 2019
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
